Rectus-Intercostal Fascial Plane Block for Liver Transplantation Donors
NCT ID: NCT07233096
Last Updated: 2026-01-08
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
NA
64 participants
INTERVENTIONAL
2025-12-22
2026-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
This prospective, randomized controlled clinical study aims to evaluate the postoperative analgesic efficacy and opioid-sparing effects of the RIFP block compared with standard intravenous analgesia in living liver donors undergoing donor hepatectomy.
Participants will be randomly assigned to two groups:
Group 1 (RIFP Block): Patients receiving an ultrasound-guided rectus-intercostal fascial plane block using 20 mL of 0.25% bupivacaine at the end of surgery, in addition to standard IV PCA (morphine).
Group 2 (Control): Patients receiving only standard IV PCA (morphine) without regional block.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Sensory Distribution and Postoperative Analgesia of Ultrasound-Guided Interfascial Plane Blocks in Living Liver Donors
NCT07252063
External Oblique Intercostal Plane Block for Liver Transplantation Recipient
NCT07233083
External Oblique Intercostal Plane Block for Liver Transplantation Donors
NCT05890079
Effect of Transversus Abdominis Plane Block on Anti-inflammatory Response
NCT04232904
Erector Spinae Plane Block in Liver Transplantation Donors
NCT05406388
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
In the RIFP group, patients will receive an ultrasound-guided RIFP block at the end of surgery and postoperative analgesia with intravenous morphine PCA. The control group will receive only intravenous morphine PCA without any regional block.
The primary outcome is total morphine consumption during the first 24 postoperative hours.
Secondary outcomes include pain scores at 1, 6, 12, and 24 hours, time to first rescue analgesia, amount of rescue analgesic used, and incidence of postoperative nausea and vomiting.
This study aims to evaluate the postoperative analgesic efficacy and opioid-sparing effect of the RIFP block in living liver donors compared with standard intravenous analgesia.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
OTHER
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Rectus Intercostal Plane Block Group
Rectus Intercostal Plane Block Group The patients in the Rectus Intercostal Plane Block group will receive a bilateral rectus intercostal plane block and patient-controlled analgesia (PCA) with morphine for postoperative analgesia.
Rectus Intercostal Plane Block
Rectus intercostal plane block will be administered bilaterally at the end of the surgery and after skin closure under ultrasound guidance
Control Group
The patients in the Control group will not receive any regional block and will receive PCA with morphine for postoperative analgesia.
Control (No Block)
Ultrasound probe placement on the same region without needle insertion or local anesthetic injection to maintain blinding.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Rectus Intercostal Plane Block
Rectus intercostal plane block will be administered bilaterally at the end of the surgery and after skin closure under ultrasound guidance
Control (No Block)
Ultrasound probe placement on the same region without needle insertion or local anesthetic injection to maintain blinding.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients with American Society of Anesthesiology (ASA) physical status I-II
* Patients scheduled for a living donor hepatectomy
Exclusion Criteria
* Coagulopathy
* Skin infection at the block area
* Advanced renal failure
* Chronic pain syndromes
* Alcohol or drug abuse
* Psychiatric disorders
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Istinye University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
istinye University
Istanbul, , Turkey (Türkiye)
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
anestezi 6
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.